PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 18, 2009New England Journal of Medicine2,931 citationsOpen Access

Mortality Results from a Randomized Prostate-Cancer Screening Trial

View Full Paper
GAGerald L. AndrioleECE. David CrawfordRGRobert L. Grubb

Key Points

  • To evaluate mortality rates from prostate cancer after screening over a follow-up period of 7 to 10 years.
  • Randomized trial design with two study groups.
  • Follow-up duration of 7 to 10 years.
  • ClinicalTrials.gov identifier NCT00002540.
  • Rate of death from prostate cancer was very low in both groups.
  • No significant difference in mortality rates between the study groups.

Abstract

After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups. (ClinicalTrials.gov number, NCT00002540.)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Andriole et al. (2009) studied this question.

synapsesocial.com/papers/69de79381d9bba5129b0c154https://doi.org/10.1056/nejmoa0810696
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk of Cardiovascular Mortality in Prostate Cancer Patients in the Rotterdam Randomized Screening Trial2006 · 18 citations
  2. 2Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality2024 · 58 citations
  3. 3Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?2004 · 48 citations
  4. 4Prostate-Specific Antigen Screening and Prostate Cancer Mortality: An Emulation of Target Trials in US Medicare2024 · 2 citations
  5. 5Prostate-specific antigen (PSA) test for prostate cancer screening2026 · 5 citations